Chao et al., characterized the immune infiltration landscape of CRC samples from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases, indicated FSTL3 is a potential immunotherapeutic target to block LNM for CRC (17). This evidence concerns the gene FSTL3 and colorectal carcinoma.